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STUDY QUESTION: What is the peripubertal outcome of recombinant human FSH (r-hFSH) treatment during minipuberty in boys with
congenital hypogonadotropic hypogonadism (CHH)?
SUMMARY ANSWER: Sertoli-cell response to r-hFSH, given during the minipuberty of infancy, appears insufﬁcient to maintain Sertoli cell
function throughout childhood, as evaluated by inhibin B measurements.
WHAT IS KNOWN ALREADY: Severe CHH in boys can be diagnosed during the minipuberty of infancy. Combined gonadotropin treat-
ment at that age is suggested to improve testicular endocrine function and future fertility, yet long-term evidence is lacking.
STUDY DESIGN, SIZE, DURATION: In this retrospective cohort study, we describe ﬁve CHH boys treated with r-hFSH in Helsinki
University Hospital or Kuopio University Hospital between 2004 and 2018. Immediate follow-up data (0.1–1.4 months after cessation of the
gonadotropin therapy) was available for four boys and long-term observations (at the age of 10.0–12.8 years) was available for three boys. As
a retrospective control cohort, we provide inhibin B values of eight untreated CHH boys at the age of 12.7–17.8 years.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Four patients had combined pituitary hormone deﬁciency, and one had
CHARGE syndrome due to a CHD7 mutation. The patients were treated at the age of 0.7–4.2 months with r-hFSH (3.4 IU/kg–7.5 IU/kg per
week in 2 or 3 s.c. doses for 3–4.5 months) combined with T (25 mg i.m. monthly for three months for the treatment of micropenis). Inhibin
B was chosen as the primary outcome measure.
MAIN RESULTS AND THE ROLE OF CHANCE: During the r-hFSH + T treatment, inhibin B increased from 76 ± 18 ng/l to 176 ±
80 ng/l (P = 0.04) and penile length increased by 81 ± 50% (P = 0.04). Unexpectedly, two boys with robust inhibin B responses in infancy
demonstrated low inhibin B values in peripuberty: declining from 290 ng/l (4 months) to 16 ng/l (12.4 years), and from 207 ng/l (6 months)
to 21 ng/l (12.8 years). All boys underwent orchiopexy at 2.0 ± 0.7 years of age. Inhibin B values in long-term follow-up, available for the
three boys, did not signiﬁcantly differ from the untreated CHH controls.
LIMITATIONS, REASONS FOR CAUTION: Limitations of this retrospective study are the small number and heterogeneity of the
patients and their treatment schemes.
WIDER IMPLICATIONS OF THE FINDINGS:We describe the ﬁrst long-term follow-up data on CHH boys treated with r-hFSH and T
as infants. The results from this small patient series suggest that the effects of infant r-hFSH treatment may be transient, and further longitu-
dinal studies are required to determine the efﬁcacy of this treatment approach to optimise the fertility potential in this patient population.
STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the Finnish foundation for Pediatric Research, the
Academy of Finland and the Emil Aaltonen Foundation. The authors have no competing interests.
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Introduction
Congenital hypogonadotropic hypogonadism (CHH), a rare cause of
delayed puberty and male infertility, is seldom diagnosed in infancy
(Boehm et al., 2015). However, in any newborn the presence of
micropenis, and bilaterally undescended testes should prompt the
evaluation of the anterior pituitary function (Grumbach, 2005; Wiygul
and Palmer, 2011). If anterior pituitary hormone deﬁciencies are diag-
nosed after a thorough work-up (including hormonal testing and MRI
imaging), the treatment is replacement of the missing hormone (GH)
or the missing end-organ hormones (thyroxine, cortisol) (Higham
et al., 2016; Pierce and Madison, 2016). However, controversy exists
about the early treatment of CHH (Bouvattier et al., 2011; Boehm
et al., 2015; Dwyer et al., 2016). The hypothalamic-pituitary-gonadal
(HPG) axis is operative already in utero, and becomes quiescent
towards term (Bouvattier et al., 2011). During the ﬁrst 24 hours of life,
there is a brief luteinising hormone (LH) surge (Corbier et al., 1990),
whereas a comprehensive re-activation of the HPG axis ensues after
the ﬁrst week of life and lasts for approximately 6 months (Andersson
et al., 1998; Grumbach, 2005). During this period in life, also known as
the minipuberty of infancy, serum gonadotropin and testicular hor-
mone levels (Leydig cell markers: testosterone and INSL3; Sertoli cell
markers: inhibin B and AMH) increase, and penile length and testicular
volume grow in size (Andersson et al., 1998; Main et al., 2006; Kuiri-
Hänninen et al., 2014). The latter is probably a surrogate of the
increase in the number of immature Sertoli cells (Cortes et al., 1987;
Bouvattier et al., 2011), which proliferate in response to FSH (Orth
et al., 1988; Arslan et al., 1993; Meachem et al., 1996). Since these cells
express androgen receptor only weakly in infants, LH-induced
endogenous testosterone does not mature the Sertoli cells or activate
spermatogenesis (Chemes et al., 2008; Rey et al., 2009). Given that
the number of Sertoli cells correlates with sperm-producing capacity
later in life (Johnson et al., 1984; Orth et al., 1988), the minipuberty of
infancy may serve as a mechanism to ensure future reproductive cap-
acity (Sharpe et al., 2003; Dwyer et al., 2016). This is therefore con-
ceivably the strongest argument favouring replacement therapy for the
missing gonadotropin stimulus in boys with severe congenital HH
(Bouvattier et al., 2011). Only few reports, however, describe the out-
come of gonadotropin treatment in boys with isolated CHH or CHH
as a part of combined pituitary hormone deﬁciency (CPHD) during the
ﬁrst year of life (Table I) (Main et al., 2002; Bougnères et al., 2008;
Sarfati et al., 2015; Lambert and Bougneres, 2016; Stoupa et al., 2017).
Although the results from these studies show that gonadotropins
increase testicular volume and probably stimulate Sertoli cell prolifer-
ation, there are currently no long-term follow-up data on these
markers.
Herein, we report ﬁve CHH patients treated with recombinant
human FSH (r-hFSH) and testosterone (T) during the ﬁrst year of life
and describe the long-term treatment responses in three of them. Our
hypothesis was that short-term neonatal treatment with r-hFSH would
result in higher inhibin B values in peripuberty compared to the
untreated CHH patients. To test this, we present a retrospective con-
trol group of eight adolescent CHH boys with no prior gonadotropin
treatment.
Materials andMethods
Patients
We reviewed the electronic patient records of ﬁve CHH boys, who were
treated in two Finnish pediatric tertiary centres (Helsinki University
Hospital and Kuopio University Hospital) between 2004 and 2018. We
describe the clinical characteristics of these patients in detail in Table II. All
ﬁve boys were born at term and had normal birth weight and birth length.
CHH was diagnosed due to an undervirilised phenotype (penile length
2.5 SD below average in all boys (Boas et al., 2006)) and low testosterone
and gonadotropin levels during minipuberty before the age of three
months (Grumbach, 2005). One boy had CHH as a part of CHARGE syn-
drome and the remaining four boys had it as a part of CPHD. The four
CPHD patients had ACTH, growth hormone and TSH deﬁciencies, which
were adequately substituted with hydrocortisone, L-thyroxine and growth
hormone (12–15 mg/m2, 3–12 μg/kg and 20–34 μg/kg/d, respectively).
In all patients, serum inhibin B was measured before (range, 3 days to
2.1 months) and during the treatment, and the maximal value during the
treatment was recorded. Follow-up data on inhibin B were available from
four boys 0.7–1.4 months after the treatment, and long-term data were
available from three boys at the age of 10–12.8 years. Testicular ultra-
sound was performed repeatedly (one to four times) for all patients. At
clinical visits, genital status was determined by palpation, testis dimensions
were measured with a ruler and testis volume was calculated with the for-
mula [length × width2 × 0.52]. Penile length was measured from the pubo-
penile skin junction to the tip of the glans.
Treatment
Table III depicts the individual treatment schedules of the ﬁve patients.
Recombinant hFSH, combined with T for the treatment of micropenis,
was initiated at the age of 2.5 ± 1.3 months (range from 0.7 months to 4.2
months). Patients received subcutaneous injections of r-hFSH for 3 to 4.5
months (Puregon®) (dose, 3.4 IU/kg to 7.5 IU/kg per week in two or
three 7.5 IU to 16.7 IU doses) and intramuscular injections of testosterone
enanthate for three months (Testoviron®, Sustanon®) (25 mg once a
month). For patient #4, T was introduced to the treatment 0.7 months
after the initiation of r-hFSH-treatment.
Currently, no dose ﬁnding studies exist on gonadotropin treatment in
infancy. The r-hFSH dose used in the this study was guided by our prior
work, in which prepubertal boys were given r-hFSH 4.5 IU/kg per week
divided in three doses, leading to testis growth and increasing inhibin B
levels (Raivio et al., 1997).
Control group and background data
To examine whether CHH boys treated with r-hFSH in infancy would have
higher inhibin B levels in long-term follow-up than CHH boys with absent
minipuberty and no prior gonadotropin treatment, we assembled a
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Table I Previous studies on gonadotropin treatment during minipuberty
Reference Treatment Patient Diagnosis Crypt-
orchidism
Micro-
penis
Age
(mo)
Treatment
duration (mo)
Before treatment During/after treatment
(highest value)
Inh-B
(ng/L)
TV (mL) Inh-B
(ng/L)
TV (mL)
Main et al. (2002) FSH 21.3 IU x2/week, LH 20–40 IU
x2/week, T suppositories 1 mg/day
1 CHH No Yes 7.9 FSH 6, LH 3.5,
T 1.5
121 0.3 268a 0.8
Bougnères et al.
(2008)
FSH 67–125 IU daily, LH 50–56 IU daily 1 CPHD No Yes 1.9 4 167 (32)b 0.6 701 (284)b 2.1
2 CHH No Yes 4.7 7 48 (9)b 0.5 426 (189)b 2.1
Sarfati et al.
(2015)
FSH 75 IU daily, LH 75 IU daily 1 CHH No Yes 1 6 24 0.3 NA 2.3
Lambert and
Bougneres
(2016)c
FSH 75–150 daily, LH 50 daily 1 CPHD Yes Yes 6 6 5 NA 55 0.6
2 CPHD Yes Yes 11 6 100 NA 505 2.0
3 CPHD Yes NA 10 6 155 NA 544 2.1
4 CHH Yes Yes 4.5 6.5 91 NA 111 0.8
5 CHH Yes Yes 2.5 6.5 73 NA 401 0.7
6 CHH Yes Yes 9 5 5 NA 287 1.2
7 CHH Yes NA 5 5 64 NA 514 0.9
8 CHH Yes Yes 0.25 6 14 NA 530 2.0
Stoupa et al.
(2017)
FSH 75 daily, LH 75–150 dailyd 1 CHH Yes Yes 4.5 6 95 (75)e 0.7 (SD not reported)e 469 (283)e 2.2 (SD not reported)e
2 CPHD No Yes 5.5 3
3 CHH Yes Yes 4.5 4
4 CHH Yes Yes 3 3
5 CHH Yes Yes 3.5 5
Inh-B Inhibin B, TV testicular volume, T testosterone, CHH congenital hypogonadotropic hypogonadism, CPHD combined pituitary hormone deﬁciency.
aMeasured during FSH + LH treatment, further increase as LH was replaced with T.
bMean (SD) for pretreatment and treatment periods.
cMicropenis is reported in this table based on penile lenght provided in the original article, if unequivocal (reference values: Boas et al., 2006).
dPatient #1, only moderately responding to LH/FSH therapy, received im. T 100 mg/m2/every two weeks for 2 months.
eNo individual data, only mean (SD) for patient series available.
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retrospective control group of CHH boys, whose inhibin B was measured
between the ages of 12.7 to 17.8 years. Their testis volume was below
2.5 mL or their testis length was less than 1 cm. Patients in the control
group are described in detail in Table IV. The control patients were treated
in Helsinki University Hospital, Kuopio University Hospital or Turku
University Hospital. One of the patients (C8) was diagnosed with CHH as
a part of CPHD at the age of one month due to low gonadotropin and tes-
tosterone levels. The remaining seven boys had no hormonal measure-
ments in infancy available, but they presented other signs of absent
minipuberty: six had bilateral cryptorchidism and/or micropenis, and one
was diagnosed with biallelic loss-of-function GNRHR mutation (C2) with
completely absent LH response in a GnRH stimulation test (Kohva et al.
2018). We have earlier described induction of puberty with gonadotropin
treatment in ﬁve of these boys (patients C1 to C5) (Kohva et al., 2018)
and the pubertal status of two of the boys (patients C6 and C7) (Varimo
et al., 2017).
In addition, we present background data of 27 boys with idiopathic short
stature (ISS) aged between 9.1 and 13.9 years in stage G1 with testicular
volume below 2 mL and treated in our clinic (Hero et al., 2005). In this
group, serving here as a reference of inhibin B in healthy prepubertal boys,
the mean Inhibin B was 88 ± 34 ng/L (range, 38 to 196 ng/L) (Fig. 1). No
abnormalities of the HPG-axis were found in any of the ISS boys at the
time of inhibin B measurement (Hero et al., 2005) or in the long-term
(Varimo T, unpublished results).
........................................................................
.............................................................................................................................................................................................
Table II Clinical characteristics of ﬁve CHH boys treated with r-hFSH and T during minipuberty.
Hormonal Cryptorchidism Diagnostic hormonal measurements for CHH
Patient Diagnosis deﬁciencies Micropenis at birth Brain MRI ﬁnding FSH LH T
#1 CHH;
CHARGE
FSH, LH Yes No hypolastic olfactory
bulbs, rudimentary
vestibular organs,
deviancies in median
line structures
0.2 <0.1 <0.2
#2 CPHD FSH, LH,
ACTH, TSH,
GH
Yes bilateral selective
hypothalamus-
pituitary
developmental
disorder
<0.1 <0.1 0.3
#3 CPHD FSH, LH,
ACTH, TSH,
GH
Yes bilateral ectopic posterior
pituitary, pituitary
hypoplacia
<0.1 <0.1 <0.2
#4 CPHD FSH, LH,
ACTH, TSH,
GH
Yes No partially ectopic
posterior pituitary,
optic infundibular
dysplasia, pituitary
stalk interruption
<0.1 0.2 <0.35
#5 CPHD;
SOD
FSH, LH,
ACTH, TSH,
GH
Yes No ectopic posterior
pituitary, hypoplastic
optic nerves
0.9 NA 0.1
Normal values median
(range)a
1.79 (0.09–2.93) 1.74 (0.90–2.64) 4.02 (1.83–6.54)
CHH congenital hypogonadotropic hypogonadism,
CHARGE syndrome (acronym from coloboma, heart defects, atresia of the choanae, retarded growth and development, genital hypoplasia and ear abnormalities),
CPHD combined pituitary hormone deﬁciency, SOD septo-optic dysplasia.
aReference values (Andersson et al., 1998).
.............................................................................................
.............................................................................................................................................................................................
Table III Treatment schemes of ﬁve infant CHH boys.
Age at onset of Treatment
Patient treatment (mo) FSH Testosterone
#1 4.2 16.6 IU x2/week for 3 mo 25mg x1/mo for 3mo
#2 0.7 8.3 IU x2/week for 3 mo 25mg x1/mo for 3mo
#3 3.1 8.3 IU x2/week for 3 mo 25mg x1/mo for 3mo
#4 1.3 7.5 IU x3/week for 3.8 mo 25mg x1/mo for 3mo
#5 3.3 16.7 IU x2/week for 4.5 mo 25mg x1/mo for 3mo
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Hormonal assays
Testosterone at the time of diagnosis was measured with radioimmuno-
assay (Lipidex-5000) until 2005, and with tandem mass spectrometer
thereafter (API 2000 and API 3000 (AB Sciex, Concord, ON, Canada)).
Gonadotropins were measured with AutoDELFIA (Wallac, Turku, Finland)
until 2011, when an electrochemiluminescence immunoassay (Roche
Diagnostics, Mannheim, Germany) was introduced. In the latter, the detec-
tion limit of the LH assay was 0.1 IU/l and inter-assay CV was less than
3%, whereas in the FSH assay, the corresponding numbers were 0.1 IU/l
and less than 5%. Inhibin B levels were determined with OBI INHB ELISA
(MCA1312KZZ, OBI-DSL, Upper Heyford, UK), replaced with INHB Gen
II ELISA (A81303) and INHB Gen II Calibrators and Controls (A81304)
(Beckman Coulter, Inc., CA, USA) in 2010. The current method for meas-
uring inhibin B has intra- and inter-assay coefﬁcients of variation of 3.8%
and 5.6% and the laboratory of Helsinki University Hospital reports values
exceeding 10 ng/L. When compared, the current Inhibin B assay showed
only 7% lower inhibin B levels than the OBI ELISA.
Statistics
Changes in inhibin B and penile length during r-hFSH + T treatment were
assessed with Wilcoxon signed-rank test. Differences in prepubertal
inhibin B values of patients treated in infancy (n = 3) and patients of the
CHH and CPHD control group (n = 8) were assessed with Mann-Whitney
U-test. Inhibin B levels in cryptorchid patients treated with r-hFSH in
infancy (current study, n = 3) were compared to patients with cryptorchid-
ism in the control group (n = 6) with Mann-Whitney U-test. The data are
presented with a mean (standard deviation) unless otherwise stated. P <
0.05 was accepted to indicate statistical signiﬁcance. Statistical analyses
were performed with SPSS statistical software for Windows, version 22.0
(SPSS, Chicago, IL, USA).
.............................................................................................................................................................................................
Table IV Control group of eight adolescent CHH boys with no prior gonadotropin treatment.
Patienta Diagnosis (mutation) Cryptorchidism Micro-penis Inhibin B
(ng/l)
Age at inhibin B
measurement (yr)
C1 KS (ANOS1 c.571 C > T (p.R191X)) Bilateral No 11 14.6
C2 nCHH (biallelic GNRHR (p.R139H)) No No 14 15.1
C3 KS (2 biallelec PROKR2 c.701 G > A (p.G234D) and c.802 C >
T (p.R268C))
No Yes 16 17.8
C4 KS (FGFR1 (p.Gly687Arg)) Unilateral Yes 24 14.6
C5 KS (ANOS1 c.571 C > T (p.R191*)) Unilateral Yes 11 12.7
C6 KS (FGFR1 c.1305_1306dupAT(p.S436YfsX3)) Bilateral No 44 13.7
C7 nCHH, CHARGE Bilateral No 13 14.3
C8 CPHD, SOD Unilateral No 17 14.4
KS Kallmann syndrome, nCHH normosmic congenital hypogonadotropic hypogonadism, CPHD combined pituitary hormone deﬁciency
SOD septo-optic dysplasia, CHARGE syndrome (acronym from coloboma, heart defects, atresia of the choanae, retarded growth and development, genital hypoplasia and ear
abnormalities)
aPatients C1 to C5 are described previously by Kohva et al. (2018) and patients C6 to C7 by Varimo et al. (2017).
Figure 1 Infant r-hFSH treatment responses and long-term outcomes in three boys with congenital hypogonadotropic hypo-
gonadism (CHH). The lines represent individual inhibin B levels in three patients with CHH (patients #3 to #5 in Tables II, III and V). Recombinant
hFSH [r-hFSH] treatment, shown in thickened lines for each patient, was initiated at the age of 0.2 ± 0.1 years: r-hFSH was administered at 3.4 IU/kg
to 7.5 IU/kg s.c. per week in two to three doses for 3–4.5 months and testosterone was administered at 25 mg i.m. once a month for three months.
Panel A describes the ﬁrst year of life of these three treated boys, and panel B the development of their inhibin B values after the age of 9 years. The
red dots in panel B mark inhibin B values of eight boys in an untreated CHH and CPHD control group (Table IV, Varimo et al., 2017; Kohva et al.,
2018). The beige box in panel B represents, as a reference, the range of inhibin B in 29 healthy prepubertal boys with idiopathic short stature aged
between 9.1 and 13.9 years in stage G1 with testicular volume below 2 mL (Hero et al., 2005)
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Ethics
The Ethics Committee of the Helsinki University Hospital has approved
this electronic, patient-record-based retrospective study, and the research
permits were granted by the Helsinki University Hospital and Kuopio
University Hospital.
Results
Hormonal levels and genital development before, during and after
r-hFSH and T treatment in the ﬁve patients are listed in Table V.
Penile length increased from 17 ± 6 mm to 29 ± 5 mm (81 ± 50%,
P = 0.04). After 3 months of T-treatment, none of the boys required
further testosterone treatment for micropenis. Of the ﬁve boys trea-
ted with r-hFSH and T, two had bilateral cryptorchidism at birth
(patients #2 and #3). The remaining three boys had scrotal testes at
birth and exhibited ascent of the testes at the age of 13 ± 10 months,
one of them (patient #1) before and two (patients #4 and #5) after
r-hFSH treatment. All ﬁve boys underwent bilateral orchiopexy at the
age of 2.0 ± 0.7 years.
The r-hFSH treatment markedly increased inhibin B levels from 76 ±
18 ng/l to 176 ± 80 ng/l (P = 0.04), and at 1.2 ± 0.4 months after ces-
sation of therapy the levels had decreased to 87 ± 70 ng/l (data
unavailable for patient #1). Long-term follow-up (11.2 ± 1.5 years) of
inhibin B levels was available for three boys. Interestingly, the rise in
inhibin B levels in response to r-hFSH given in infancy appeared to sub-
side completely (Fig. 1). Two of the boys with a marked inhibin B
response in infancy demonstrated declined values from 290 ng/l to
16 ng/l (patient #4; age 12.4 years) and from 207 ng/l to 21 ng/l
(patient #5; age 12.8 years). The third boy (patient #3) showed a
decline of inhibin B from 74 ng/l during the treatment to 10 ng/l by
the age of 5.6 years. At that time, 2.6 years after bilateral orchiopexy,
the ultrasound detected no vascular network in his testicular struc-
tures. Although his inhibin B levels remained at the detection limit of
10 ng/l in follow-up, AMH levels were measurable (0.33 to 0.6 μg/l at
a lower detection limit of 0.03 μg/l), suggesting some persistent Sertoli
cell activity. We compared the long-term follow-up inhibin B values of
patients #3 to #5 to a cohort of prepubertal CHH and CPHD boys
(n = 8, Table IV), who had not received r-hFSH treatment during their
minipuberty. Their mean inhibin B level was 19 ± 11 ng/l (range from
11 ng/l to 44 ng/l) at the age of 14.7 ± 1.5 years. The inhibin B values
in the three r-FSH-treated patients (inhibin B 16 ± 6 ng/l) did not differ
from inhibin B values in the untreated control group (Fig. 1). As all the
boys treated in infancy had cryptorchidism, we limited the comparison
to the cryptorchid patients in the control group (n = 6, inhibin B 20 ±
13 ng/l) to account for the possible confounding effect, but there still
was no signiﬁcant difference between the two groups.
Discussion
The current study is, to our knowledge, the ﬁrst long-term follow-up
report on boys with CHH treated with recombinant FSH in infancy.
Treatment responses to gonadotropins administered in infancy in
terms of testicular growth and Sertoli cell markers had been reported
in only 17 patients, summarised in Table I (Main et al., 2002;
Bougnères et al., 2008; Sarfati et al., 2015; Lambert and Bougneres,
2016; Stoupa et al., 2017). In 2002, Main et al. described a 7.9-month-
old CHH male treated with a moderate dose of gonadotropins (FSH
21.3 IU and LH 20 IU) twice a week for six months with a good
response in inhibin B and testis size. Thereafter, several studies with
larger daily FSH and LH doses (FSH 67–150 IU and LH 50–150 IU)
have shown further promising results in CHH and CPHD patients
(Bougnères et al., 2008; Sarfati et al., 2015; Lambert and Bougneres,
2016; Stoupa et al., 2017). Thus, these studies reporting the immedi-
ate outcomes of infant FSH treatment suggest that mimicking the
physiologic gonadotropin secretion of minipuberty holds promises for
improvement of fertility and testicular endocrine function (Bouvattier
et al., 2011).
It has been unknown, however, whether FSH treatment during
infancy provides long-lasting advantages in terms of adult male repro-
ductive health (Bouvattier et al., 2011). In this study we chose inhibin B
as the primary outcome since: (i) it has been used in previous studies
describing short-term FSH responses in infants with CHH (Table I); (ii)
it has been shown to reﬂect FSH action of immature Sertoli cells
(Anawalt et al., 1996; Raivio et al., 1997; Grinspon et al., 2018); (iii)
................................................... ................................ .............................................................
.............................................................................................................................................................................................
Table V Clinical characteristics and serum concentration of hormones in ﬁve CHH boys treated with r-hFSH + T in
infancy.
Before treatment During treatment After treatmenta Follow-upb
Patient Inhibin
B (ng/l)
FSH
(IU/l)
Testis
size
Penile
length
(mm)
Max
inhibin
B (ng/l)
Max FSH
(IU/l)
Inhibin
B (ng/l)
Testis
size
Age at
orchiopexy
(mo)
Penile
length
(mm)
Inhibin
B (ng/l)
#1 66 0.2 0.12 ml 14 169 3.5 NA 0.1 ml 16 31 NA
#2 101 <0.1 NA 10 139 NA 62 10 mm la 22 24 NA
#3 68 <0.1 10 mm
la
15 74 0.4 22 4 mm la 37 24 10
#4 57 <0.1 0.15 ml 24 290 3.4 186 0.4 ml 26 35 16
#5 90 0.9 NA 23 207 2.1 77 13 mm l.
sin
17 30 21
aWithin 2 months after cessation of treatment.
bAfter a 9.5–12.2 year interim period.
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the physiological changes in inhibin B during the ﬁrst few years of life
and in peripuberty have been described (Andersson et al., 1997, 1998;
Hero et al., 2012); and (iv) inhibin B was the clinicians’ choice more
than 10 years ago (i.e. at the beginning of this study period) and cur-
rently (Kohva et al. 2018) to monitor their patients on gonadotropin
treatment. The goal of gonadotropin treatment in infancy is to mimic
the physiological actions of minipuberty, where inhibin B ﬁrst reaches
values comparable to those of adult males and then decreases, but
persists at measurable levels (Andersson et al., 1998). Low inhibin B is
one of the acceptable markers to discriminate CHH boys from peers
with constitutional delay of growth and puberty (Varimo et al., 2017).
We thus hypothesised that r-hFSH treatment in infant CHH boys
would result in higher, more physiological levels of inhibin B in child-
hood compared to untreated CHH patients, but the current data did
not support this hypothesis.
Three boys in the current study treated with r-hFSH and T in infancy
had very low inhibin B values in the long-term follow-up. Two of them
had a particularly good inhibin B response to r-hFSH but very low
levels in peripuberty. This suggests that the treatment response in
inhibin B, indicating increase in Sertoli cell number and activity, might
not be persistent over a time-period of more than 10 years. The data
on patient #3 with a low inhibin B response to r-hFSH as an infant,
bilateral cryptorchidism, extremely small testis size of 4 mm measured
after treatment during orchiopexy and low inhibin B in the long-term
follow-up do not support long-lasting effects of infant r-hFSH treat-
ment either. It has to be noted, however, that we do not know
whether inhibin B reﬂects the assets of the infant gonadotropin treat-
ment sufﬁciently. More longitudinal data on other parameters, such as
sperm count after induction of puberty, are needed.
It is unclear what kind of treatment scheme should be followed after
the infant gonadotropin treatment towards induction of puberty in
these patients. For example, we speculate that continuous low-dose
FSH stimulus during childhood should be considered to sustain both
Sertoli cell function and number. The rationale behind this approach is
that FSH secretion in healthy prepubertal boys is not unmeasurably
low (Dunkel et al., 1990; Wu et al., 1991) and Sertoli cells appear
responsive for FSH throughout the childhood hiatus of low gonado-
tropin secretion in primates (Rey et al., 1993) and humans (Raivio
et al., 1997). Indeed, Countant et al. were able to associate continuous
activation of G protein-coupled receptors (likely including those of
FSHR) in McCune-Albright syndrome with blunted FSH response to
GnRH stimulation, elevated inhibin B and macro-orchidism (Coutant
et al., 2001), all consistent with active proliferation of immature Sertoli
cells.
Limitations of this study arise from heterogeneity of the patients,
variation in their treatment schemes, two different measurement tech-
niques (ruler and ultrasound) for testicular size determination and the
lack of testis measurements in some of the patients. Dose-ﬁnding stud-
ies on this topic are currently lacking: we do not know whether a lar-
ger r-hFSH dose would result in more notable changes in inhibin B or
testis volume. It is also important to acknowledge that it is not known
whether increasing the intratesticular testosterone with LH or hCG
would produce more sustainable results in terms of Sertoli cell func-
tion. Furthermore, controversy exists on whether hormonal interven-
tion (GnRH, hCG or LH) should be considered for bilateral
cryptorchidism in CHH patients, although the Nordic consensus
recommends surgical treatment (Ritzén et al., 2007; Bu et al., 2016;
Lambert and Bougneres, 2016). All of the ﬁve patients in this series
treated with r-hFSH and T required bilateral orchiopexy, three of
them due to ascent of the testes. Given the small number of the
patients, the results of this retrospective study should be interpreted
with appropriate caution.
In summary, all ﬁve CHH boys responded to r-hFSH and T treat-
ment with increased inhibin B levels and penile length. According to
these data, exogenous T does not inhibit the Sertoli cell activity.
However, the long-term data suggest that the effects of infant r-hFSH
treatment on Sertoli cell function may be transient. More longitudinal
studies are clearly required to address the effect of this treatment
approach on future fertility and to optimise the hormonal supplemen-
tation therapy of infant patients with CHH, small testis size and crypt-
orchidism, as such patients are at the greatest risk of infertility (Liu
et al., 2009; Rastrelli et al., 2014).
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